Clinical Trials

Ongoing clinical trials in molecular imaging and radiotheranostics. Sorted by date of last update.

Title Phase Last Update

Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

Phase 1

Last update: January 23

Phase 1 January 23

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Phase 2

Last update: January 23

Phase 2 January 23

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma

N/A

Last update: January 23

N/A January 23

Comparing Retreatment of Lu-177-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Phase 2

Last update: January 23

Phase 2 January 23

Radiation Medication (Radium-223 Dichloride) versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1

Last update: January 23

Phase 1 January 23

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu-177 Dotatate) for Pancreatic Neuroendocrine Tumors

Phase 1

Last update: January 23

Phase 1 January 23

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used with Targeted Radiation-based Treatment (Lutetium Lu-177 Dotatate), Compared to Lutetium Lu-177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Phase 2

Last update: January 23

Phase 2 January 23

Testing Lutetium Lu-177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Phase 2

Last update: January 23

Phase 2 January 23

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu-177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Phase 2

Last update: January 23

Phase 2 January 23

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Phase 2

Last update: January 23

Phase 2 January 23